Prostamax

Prostamax is a prostate-derived polypeptide complex from the Khavinson bioregulator family, researched for prostate-tissue-targeted bioregulation and urological function. Like Thymalin, Prostamax is a tissue extract rather than a single defined peptide sequence — derived from bovine or porcine prostate tissue and containing multiple constituent peptides. It is approved for medical use in Russia and several CIS countries for benign prostatic hyperplasia and related urological conditions but has no FDA, EMA, or major Western regulatory approval.

What is Prostamax and how does the prostate-targeted bioregulatory mechanism work?

Prostamax is a Prostamax is a synthetic tetrapeptide — Lys-Glu-Asp-Pro (KEDP) — from the Khavinson group's designed "Cytogen" short-peptide family. It is a single defined peptide made by synthesis, not an extract of prostate tissue. Within the Khavinson framework it is designated a "prostate bioregulator," but that organ-target designation is the group's own proposal, not established biology., proposed to restore prostate tissue function through tissue-specific bioregulatory signaling. The Khavinson framework proposes that Prostamax's constituent peptides enter prostate cell nuclei and modulate gene expression in pathways related to glandular function, inflammation control, and urological tissue homeostasis. As with Thymalin, the multi-component nature is both a mechanistic claim (multiple peptides acting synergistically) and a regulatory challenge (harder to standardize across batches).

Source: Short Peptides Regulate Gene Expression, Khavinson V.Kh., Linkova N.S., Tarnovskaya S.I. (optional, non-blocking follow-up: confirm full author list), Bulletin of Experimental Biology and Medicine, 2016 · Evidence level: russian clinical practice (approved); Khavinson-group clinical research; independent replication limited

What does the research show for Prostamax?

Russian clinical practice includes Prostamax for benign prostatic hyperplasia (BPH), chronic prostatitis, and adjunctive prostate-recovery contexts. Published research on Prostamax comes almost entirely from one group — Vladimir Khavinson's, at the St Petersburg Institute of Bioregulation and Gerontology, and collaborators — and is largely preclinical (effects on lymphocyte chromatin and gene expression in cell and rodent models). Any reported human use is non-blinded and single-institution; no Western-standard randomized controlled trial of Prostamax has been published as of August 2026, and independent replication outside this group is limited.

Evidence level: russian clinical (approved use); Khavinson-group research; independent replication limited

How does Prostamax compare to other Khavinson bioregulators?

Prostamax is one of two polypeptide-extract bioregulators in the Khavinson cluster (alongside Thymalin), distinguishing it from the synthesized single-sequence tripeptides and tetrapeptides.

What are the documented side effects of Prostamax?

Side effects in Russian clinical use are generally mild — injection-site reactions, occasional transient flushing. As a polypeptide extract derived from animal tissue, theoretical concerns include allergic reactions and the broader animal-derived-biologic risk profile. Long-term safety in approved Russian clinical practice spans years; Western long-term safety data is not available.

Evidence level: russian clinical safety record; independent verification limited

What is the regulatory status of Prostamax?

Prostamax is approved for medical use in Russia and several CIS countries for BPH and related urological indications. It is not approved by the FDA, EMA, or major Western regulators. Outside approved markets, Prostamax is sold as a research-use-only compound by third-party laboratories. Regulatory context in FDA peptide regulation 2025–2026 timeline.

Why does Prostamax vendor verification matter?

As with Thymalin, Prostamax's polypeptide-extract nature makes identity verification fundamentally harder than for synthesized peptides — HPLC profiles show complex multi-component patterns, and individual vendor batches may vary substantially. Some research-grade vendors sell "Prostamax" that may not match the genuine Russian-clinical extract composition. Independent third-party testing is essential. Guidance in how-to-test-peptides hub.

How does Peptigrity verify Prostamax vendors?

Peptigrity collects independent third-party Certificates of Analysis for Prostamax from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. Tests in the database come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate. Because Prostamax is a short synthetic peptide with a single defined sequence, mass-spectrometry identity confirmation against the expected KEDP mass is straightforward — and important, since same-length Khavinson peptides are easily mislabeled. Methodology in how we calculate trust scores.

Frequently asked questions

What does Prostamax do?

Within the Khavinson framework Prostamax (the Lys-Glu-Asp-Pro tetrapeptide) is proposed to act on prostate tissue through epigenetic gene-expression modulation, but that tissue-target claim rests on single-group preclinical work. It is not an FDA/EMA-approved drug, and Peptigrity could not verify a Russian pharmaceutical registration for the synthetic Prostamax peptide (as distinct from registered prostate-tissue-extract preparations). Western-standard Phase 2/3 efficacy data does not exist.

Is Prostamax a single peptide or an extract?

Prostamax is a single defined synthetic peptide — the tetrapeptide Lys-Glu-Asp-Pro (KEDP) — not a tissue extract. It is sometimes confused with prostate-tissue-extract preparations (such as Prostatilen), which are different products. This distinguishes it from synthesized Khavinson bioregulators like Testagen or Vesugen.

Source: Short Peptides Regulate Gene Expression, Khavinson V.Kh., Linkova N.S., Tarnovskaya S.I. (optional, non-blocking follow-up: confirm full author list), Bulletin of Experimental Biology and Medicine, 2016

Is Prostamax legal to purchase?

Prostamax is approved for medical use in Russia and CIS countries and is legal to purchase as a research chemical for laboratory use in most other jurisdictions, but it is not approved for human consumption in the US, EU, or most Western markets. Country breakdown in peptide legal status guide.

Will Prostamax be FDA-approved?

No active FDA approval pathway exists for Prostamax as of August 2026. Bioregulator peptides as a class are not being advanced through FDA clinical development by any pharmaceutical sponsor.

How can I verify a Prostamax vendor is selling real product?

An independent, batch-matched third-party HPLC certificate of analysis for purity, plus mass-spectrometry confirmation that the mass matches the expected Lys-Glu-Asp-Pro tetrapeptide (not a similar-length sibling bioregulator). COA interpretation in red flags in peptide certificates of analysis.

Does Peptigrity recommend a Prostamax dose?

No. Peptigrity is an independent review platform, not a medical authority. Russian clinical practice protocols vary by indication. Anyone considering use should consult a licensed physician.

This section is for educational and informational purposes only and does not constitute medical advice. Prostamax is approved for medical use in Russia and CIS countries but is not approved by the FDA, EMA, or other major Western regulators. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.